← Back to Search

Cytokine

Arm I for Melanoma

Phase 2
Waitlist Available
Led By William Carson
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

Phase II trial to study the effectiveness of combining interleukin-12 and interferon alfa in treating patients who have metastatic malignant melanoma. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Interferon alfa may interfere with the growth of the cancer cells. Combining interleukin-12 and interferon alfa may kill more tumor cells.

Eligible Conditions
  • Melanoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PFS
Response rate

Trial Design

1Treatment groups
Experimental Treatment
Group I: Arm IExperimental Treatment3 Interventions
Patients receive interleukin-12 IV over 5-15 seconds on day 1 and interferon alfa subcutaneously on days 2-6. Treatment repeats every 2 weeks in the absence of unacceptable toxicity. Patients are reassessed after 6 courses. Patients with a complete response receive 2 additional courses. Patients with a partial response or stable disease continue treatment in the absence of disease progression.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Edodekin alfa
Not yet FDA approved
Benzalkonium
FDA approved

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,704 Previous Clinical Trials
40,931,382 Total Patients Enrolled
558 Trials studying Melanoma
193,382 Patients Enrolled for Melanoma
William CarsonPrincipal InvestigatorCancer and Leukemia Group B
4 Previous Clinical Trials
123 Total Patients Enrolled
1 Trials studying Melanoma
57 Patients Enrolled for Melanoma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
2001. "Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00026143.
~3 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top